急性冠脉综合征后白介素-6与C反应蛋白的预后价值
基于ODYSSEY OUTCOMES试验的事后分析,在11 817例近期急性冠脉综合征患者中评估基线hsCRP与IL-6对主要不良心血管事件(MACE)和全因死亡的预后价值。结果显示hsCRP独立预测MACE而IL-6不独立预测,两者均独立预测死亡,联合提供互补预后信息。
要点
- 近期ACS患者中,基线hsCRP独立预测MACE,IL-6不独立预测MACE。
- hsCRP与IL-6均独立预测全因死亡,两者联合提供互补预后信息。
- 两者同时升高时MACE和死亡风险显著升高,仅一项升高时未显著升高。
核心结论
- 在近期ACS患者中,hsCRP独立预测MACE而IL-6不独立预测,两者均独立预测死亡。
- hsCRP与IL-6联合提供互补的预后信息,hsCRP提供超越IL-6的独立炎症风险信息。
研究设计与样本
- ODYSSEY OUTCOMES试验的事后分析,比较alirocumab与安慰剂在优化他汀治疗后的ACS患者。
- 共11 817例患者有基线hsCRP和IL-6数据,采用比例风险模型分析对数转换的hsCRP和IL-6与MACE及全因死亡的关系。
主要发现
- 中位hsCRP为1.54 mg/L,中位IL-6为5.00 pg/ml,中位LDL-C为86 mg/dl,hsCRP与IL-6中度相关(r=0.52)。
- 1306例发生MACE主要终点,458例死亡。
- 互相调整后,hsCRP独立预测MACE(P<.0001),IL-6不独立预测(P=.21);两者均独立预测死亡(hsCRP P<.0001,IL-6 P=.0003)。
- 上述关系不依赖于治疗分组(所有交互P>.25)。
关键数值与推荐
- hsCRP以2 mg/L、IL-6以5 pg/ml二分时,两者同时升高者MACE和死亡风险显著升高,仅一项升高者未显著升高。
临床怎么用
- 近期ACS患者可检测hsCRP和IL-6以评估炎症相关预后风险,两者联合提供互补信息。
- hsCRP独立于IL-6提供炎症风险信息,支持hsCRP作为ACS后炎症风险标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: After acute coronary syndrome (ACS), high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) levels have been associated with risk of major adverse cardiovascular events (MACE). Whether the prognostic information provided by hsCRP and IL-6 is independent and complementary after ACS is unclear. METHODS: The ODYSSEY OUTCOMES trial compared alirocumab with placebo in post-ACS patients on optimized statin therapy. In post hoc analyses, the relation between log-transformed hsCRP and IL-6 levels and risk of MACE and all-cause death was assessed in proportional hazards models. RESULTS: A total of 11 817 patients had baseline hsCRP and IL-6 data; 1306 had a MACE primary endpoint and 458 died. Median hsCRP, IL-6, and low-density lipoprotein cholesterol (LDL-C) were 1.54 mg/L, 5.00 pg/ml, and 86 mg/dl, respectively. hsCRP and IL-6 had moderate correlation (r = 0.52). In models for one biomarker adjusted for the other biomarker, treatment assignment, age, sex, diabetes, LDL-C, and time since index ACS, hsCRP was a significant independent predictor of MACE (P < .0001) and IL-6 was not (P = .21); both independently predicted death (P < .0001 for hsCRP and P = .0003 for IL-6). Relationships did not depend on treatment (all Pinteraction > .25). When dichotomized at 2 mg/L (hsCRP) and 5 pg/ml (IL-6), risks of MACE and death were significantly elevated when both, but not when one marker was elevated. CONCLUSIONS: In patients with recent ACS, hsCRP independently predicted MACE, while both hsCRP and IL-6 predicted death. Together, the two markers provided complementary prognostic information. hsCRP conveys independent information on inflammatory risk beyond that provided by IL-6.
引用
- Jukema, Van Neer, Szarek, et al. Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome. Eur Heart J. 2026. PMID: 42185072. doi:10.1093/eurheartj/ehag317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。